divarasib

1. 09:40
   中文产业新闻精选

   KRAS 突变肺癌：罗氏制药 divarasib 头对头，338 例入组缓解率 58.4%

   罗氏 10 月 25 日公布 divarasib 三期头对头试验结果，338 例经治 KRAS G12C 肺癌患者随机分组，中位总生存 17.7 个月对 12.0 个月，死亡风险降低 44%。原文称这是下一代 KRAS G12C 抑制剂与已上市一代抑制剂之间的首个三期头对头研究，标题披露缓解率 58.4%。

2. 05:04
   ESMO 2026 现场信号

   Not all KRAS G12C inhibitors are equal. Once approved, divarasib could be our preferred option after first line, and the real question is how quickly we move it to the first line.
3. 04:06
   ESMO 2026 现场信号

   #ESMO26
4. 02:44
   ESMO 2026 现场信号

   Divarasib beats adagrasib and sotorasib in the 2nd line treatment of KRAS G12C mutated NSCLC. This sets a new standard for now, but I’m hopeful that this is just the first of many
5. 00:12
   ESMO 2026 现场信号

   Exciting!
6. 00:08
   ESMO 2026 现场信号

   The last dance for KRAS inhibitors. Divarasib . Nice discussion. Systemic cross over should be reconsiderd when PFS is the primar end point. It will be intr to see future data f

1. 23:56
   ESMO 2026 现场信号

   Divarasib. New KRAS G12C inhibitor. New Diva in town ? Let's wait for trial against docetaxel 🤐🙂 @OncoAlert @myESMO #esmo26
2. 23:45
   ESMO 2026 现场信号

   A new SoC enters the #KRASG12C room breaking down the door! Divarasib improves both PFS and OS vs Sotorasib/Adagrasib
3. 23:42
   ESMO 2026 现场信号

   There was a good discussion re reimbursement at today's #Esmo26 press conf. If you're a health authority that doesn't reimburse Lumakras, do you care that divarasib has beaten Luma
4. 23:40
   ESMO 2026 现场信号

   Divarasib significantly improved PFS (9.8 vs 5.7 m) and OS (12 vs 17.7) vs control (soto or ada) with a manageable safety profile (GI toxicity) in previously treated advanced/met
5. 23:36
   ESMO 2026 现场信号

   Roche's KRAS G12C inhibitor divarasib lives up to expectations in lung cancer study $RHHBY #ESMO2026 https://firstwordpharma.com/story/8267209
6. 23:36
   ESMO 2026 现场信号

   Divarasib PFS & OS, vs approved KRAS G12C inhibitors in relapsed G12Cm NSCLC. Will this get a standing ovation?? #ESMO26 $RHHBY
7. 20:53
   ESMO 2026 现场信号

   🫁#ESMO26 I Divarasib reduce el riesgo de muerte un 44% en cáncer de #pulmón con KRAS G12C frente a las terapias actuales.
8. 16:13
   ESMO 2026 现场信号

   Divarasib's benefit over approved KRAS G12C inhibitors is now clear, from the #ESMO26 abstract $RHHBY $AMGN $BMY

当前热度 82·可比范围峰值 95（10月26日 06:00）·近 24 小时可比范围变化 –·当前参与者 12

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。